Jiangsu Hengrui Pharmaceuticals
Jiangsu Hengrui is China's largest innovative pharma, maker of the PD-1 antibody camrelizumab and a broad ADC pipeline.
Camrelizumab is approved in China across HCC, NSCLC, oesophageal and nasopharyngeal cancers; the camrelizumab-rivoceranib combination (with Elevar/HLB) is under FDA review. Extensive ADC and GLP-1 pipelines with multiple ex-China licensing deals since 2023.
Pages like this
not linked directly; found by shared links- TrialCARES-310
Shares Camrelizumab + rivoceranib, Hepatocellular carcinoma.
- CompanyElevar Therapeutics (HLB)
Shares Camrelizumab + rivoceranib, Hepatocellular carcinoma.
- InstitutionChang Gung Memorial Hospital
Shares Oesophageal cancer, Hepatocellular carcinoma, Non-small-cell lung cancer.
- IdeaMinimum alcohol pricing evaluated with cancer endpoints
- InstitutionOsaka International Cancer Institute
Shares Oesophageal cancer, Hepatocellular carcinoma, Non-small-cell lung cancer.
- InstitutionKyushu University Hospital
Shares Oesophageal cancer, Hepatocellular carcinoma, Non-small-cell lung cancer.
- ProductCamrelizumab
Shares Nasopharyngeal carcinoma, Oesophageal cancer, Hepatocellular carcinoma, Non-small-cell lung cancer.
- PersonJie He